Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | ESR1 | P03372 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | SHBG | P04278 | 2/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.72 |
| ▸ | FYN | P06241 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone Benzoate SCHEMBL18467888 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAESR1SMN1; SMN2SHBG | |
| Estrone Benzoate SCHEMBL1270198 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAESR1SMN1; SMN2SHBG | |
| SCHEMBL17585035 | 0.90 | CYP3A4 (0.81) | CYP3A4LMNAESR1SMN1; SMN2SHBG | |
| SCHEMBL9651494 | 0.89 | CYP3A4 (0.80) | CYP3A4LMNAESR1SMN1; SMN2SHBG | |
| SCHEMBL9011119 | 0.89 | CYP3A4 (0.80) | CYP3A4LMNAESR1SMN1; SMN2SHBG | |
| SCHEMBL1977541 | 0.89 | CYP3A4 (0.80) | CYP3A4LMNAESR1SMN1; SMN2SHBG | |
| SCHEMBL12774793 | 0.88 | CYP3A4 (0.78) | CYP3A4LMNAESR1SMN1; SMN2SHBG | |
| Iodide SCHEMBL9011129 | 0.88 | CYP3A4 (0.77) | CYP3A4LMNAESR1SMN1; SMN2SHBG | |
| Estrone Acetate SCHEMBL6241050 | 0.87 | CYP3A4 (0.76) | CYP3A4LMNAESR1SMN1; SMN2SHBG | |
| Estrone Acetate SCHEMBL20006536 | 0.87 | CYP3A4 (0.76) | CYP3A4LMNAESR1SMN1; SMN2SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295217-A1 | 2-METHOXYESTRADIOL DERIVATIVES AND MEDICAL USES THEREOF | INSTITUT PASTEUR KOREA (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230295217-A1 | 2-METHOXYESTRADIOL DERIVATIVES AND MEDICAL USES THEREOF | INSTITUT PASTEUR KOREA (KR) | 2023-09-21 | — | — | US | disclosed |
| WO-2021075860-A1 | 2-METHOXYESTRADIOL DERIVATIVES AND MEDICAL USES THEREOF | INSTITUT PASTEUR KOREA (KR) | 2021-04-22 | — | — | WO | disclosed |
| US-9988417-B2 | Process for the preparation of estetrol | CRYSTAL PHARMA, S.A.U. (ES) | 2018-06-05 | — | — | US | disclosed |
| US-9988417-B2 | Process for the preparation of estetrol | CRYSTAL PHARMA, S.A.U. (ES) | 2018-06-05 | — | — | US | disclosed |
| EP-3046928-B1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA SAU (ES) | 2017-02-08 | — | — | EP | disclosed |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-11 | — | — | US | disclosed |
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-11 | — | — | US | disclosed |
| WO-2015040051-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | CRYSTAL PHARMA, S.A.U. (ES) | 2015-03-26 | — | — | WO | disclosed |
| WO-2013034780-A2 | PROCESS FOR THE PREPARATION OF ESTETROL AND RELATED COMPOUNDS | CRYSTAL PHARMA, S.A.U. (ES) | 2013-03-14 | — | — | WO | disclosed |
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-08 | — | — | US | disclosed |
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229885-A1 | PROCESS FOR THE PREPARATION OF ESTETROL | SRD5A2, VKORC1L1, SRD5A1 | CYP3A4 27/4885LMNA 2098/4885ESR1 7/4885 |
| US-20070259837-A1 | Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy | UTRN, MTPN, NR3C1 | CYP3A4 3949/4885LMNA 348/4885ESR1 2263/4885 |
| US-20230295217-A1 | 2-METHOXYESTRADIOL DERIVATIVES AND MEDICAL USES THEREOF | GPER1, ESRRB, ESR2 | CYP3A4 742/4885LMNA 2483/4885ESR1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.